Almost every big pharma and big biotech, jostling to get a foot into the promising field of immuno-oncology or further strengthen their position, has been relying on partnering to improve their standing. If the steady increase in deal valuations is any indication, interest isn’t waning.
In the last 10 months alone more than a dozen immuno-oncology deals have been signed with an up-front value of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?